Literature DB >> 6809393

The effects of almitrine on the ventilatory response to hypoxia and hypercapnia in normal subjects.

J R Stradling, P Barnes, N B Pride.   

Abstract

1. Almitrine at a dose of 0.5 mg h-1 kg-1 given intravenously over 2 h had no effect on resting ventilation in normal males. 2. There was a small, but insignificant, rise in the hypercapnic drive to breathe as compared with placebo. 3. A large rise in the hypoxic drive to breathe was seen in response to almitrine. 4. These findings support the claim that almitrine has its action on ventilation via the peripheral chemoreceptors. 5. No correlation between blood levels of almitrine and the rise in hypoxic response was seen.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6809393     DOI: 10.1042/cs0630401

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  5 in total

1.  Almitrine bismesylate and oxygen therapy in hypoxic cor pulmonale.

Authors:  T W Evans; J Tweney; J C Waterhouse; J Nichol; A J Suggett; P Howard
Journal:  Thorax       Date:  1990-01       Impact factor: 9.139

2.  Circulatory and respiratory effects of infused adenosine in conscious man.

Authors:  R W Fuller; D L Maxwell; T B Conradson; C M Dixon; P J Barnes
Journal:  Br J Clin Pharmacol       Date:  1987-09       Impact factor: 4.335

Review 3.  Respiratory and allergic disease. II. Chronic obstructive airways disease and respiratory infections.

Authors:  K F Chung; P J Barnes
Journal:  Br Med J (Clin Res Ed)       Date:  1988-01-09

4.  Comparison of almitrine bismesylate and medroxyprogesterone acetate on oxygenation during wakefulness and sleep in patients with chronic obstructive lung disease.

Authors:  E Daskalopoulou; D Patakas; V Tsara; F Zoglopitis; E Maniki
Journal:  Thorax       Date:  1990-09       Impact factor: 9.139

Review 5.  Hypoxic pulmonary vasoconstriction.

Authors:  J T Sylvester; Larissa A Shimoda; Philip I Aaronson; Jeremy P T Ward
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 46.500

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.